Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

@article{Patel2007EffectsOA,
  title={Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial},
  author={Anushka Patel},
  journal={The Lancet},
  year={2007},
  volume={370},
  pages={829-840}
}

Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence

TLDR
Routine treatment with the fixed combination of perindopril and indapamide was well tolerated and reduced the risk of death and major vascular events, regardless of the initial blood pressure level or concomitant treatments received.

Reducing cardiovascular risk in diabetes: insights from the ADVANCE study

TLDR
Routine administration of a fixed combination of perindopril and indapamide to patients with type 2 diabetes and with a good controlled blood pressure was well tolerated and reduced the risks of major vascular events, including death, but it remains the doubt if these results have been obtained because of the better pressure control or are specific of this preconstructed association.

Effects of Combination of Perindopril, Indapamide, and Calcium Channel Blockers in Patients With Type 2 Diabetes Mellitus: Results From the Action in Diabetes and Vascular Disease: Preterax and Diamicron Controlled Evaluation (ADVANCE) Trial

TLDR
The combination of perindopril and indapamide with CCBs seems to provide further protection against mortality in patients with type 2 diabetes mellitus.

Trials That Matter: The Effect of a Fixed-Dose Combination of an Angiotensin-Converting Enzyme Inhibitor and a Diuretic on the Complications of Type 2 Diabetes

TLDR
The ADVANCE trial was an empirical test of principle for the blood pressurelowering component of a future combination polypill in this population of patients with type 2 diabetes, and showed that a fixed, low-dose combination of perindopril and indapamide added to standard background antihypertensive treatment could safely reduce both microvascular and macrovascular complications.

Should all patients with type 2 diabetes receive initial combination therapy: an assessment of the ADVANCE trial.

TLDR
It is concluded that a fixed dose combination of perindopril and indapamide should be recommended for all patients with type 2 diabetes, irrespective of their existing blood pressure, based on data from the ADVANCE trial.

Combined Effects of Routine Blood Pressure Lowering and Intensive Glucose Control on Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes

TLDR
The effects of routine blood pressure lowering and intensive glucose control were independent of one another, and when combined, they produced additional reductions in clinically relevant outcomes.

Routine blood pressure lowering and intensive glucose control in patients with Type 2 diabetes: the ADVANCE trial

TLDR
Intensive glucose control was not associated with a significant reduction in macrovascular events; however, unlike reports from the recently reported Action to Control Cardiovascular Risk in Diabetes (ACCORD), there was no evidence of any increase in all-cause mortality or cardiovascular death with more intensive glucose control.

Vascular legacy beyond blood pressure control: benefits of perindopril/indapamide combination in hypertensive patients with diabetes

TLDR
Treatment with perindopril/indapamide has microvascular and macrovascular effects that extend beyond blood pressure lowering and that this treatment might confer a long-lasting beneficial vascular legacy.

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

TLDR
In the large diabetic subgroup in the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial, the benefits of amlodipine-based treatment, compared with atenolol- based treatment, on the incidence of total cardiovascular events and procedures was significant and similar to that observed in the total trial population.

Choice of ACE inhibitor combinations in hypertensive patients with type 2 diabetes: update after recent clinical trials

TLDR
The present review will focus on different ACE inhibitor combinations in the treatment of patients with type 2 diabetes mellitus and hypertension, in the light of recent clinical trials, including GUARD and ACCOMPLISH.
...

References

SHOWING 1-10 OF 33 REFERENCES

Role of blood pressure targets and specific antihypertensive agents used to prevent diabetic nephropathy and delay its progression.

TLDR
On the basis of available RCT evidence, ACEi and ARB are the only agents with proven renal benefit in patients who have diabetes with no nephropathy and the only agent with proven survival benefit in Patients who haveabetes with nephrolysis.

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

TLDR
Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to Diabetes, progression of diabetic retinopathy, and deterioration in visual acuity.

Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.

TLDR
These overviews showed that the short- to-medium-term effects on major cardiovascular events of the BP-lowering regimens studied were broadly comparable for patients with and without diabetes.

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

TLDR
The effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial were compared.